China Aoxing Pharmaceutical Will Present at the Third Annual Adam Friedman China Growth Conference on November 7 and Will File Its Presentation with the SEC as a Form 8K

Wednesday, November 7, 2007 General News J E 4
NEW YORK, Nov. 6 China Aoxing PharmaceuticalCompany, Inc. (OTC Bulletin Board: CAXG), which has the largest manufacturingfacility and product pipeline for highly regulated narcotic medicines and painmedication in China, announced today that it will present at the Third AnnualAdam Friedman China Growth Conference at the Princeton Club in New York Cityon November 7.

The Company's presentation will be filed with the U.S. Securities andExchange Commission as a Form 8K.

About China Aoxing Pharmaceutical Company, Inc.

China Aoxing Pharmaceutical Company, Inc. (OTC Bulletin Board: CAXG) is apharmaceutical company in China specializing in research, development,manufacturing and distribution of a variety of narcotics and pain managementproducts. Headquartered in Shijiazhuang City, the pharmaceutical capital ofChina, outside of Beijing, the Company has the largest product pipeline andlargest manufacturing facility (1.2 million sq. ft.) for highly regulatednarcotic medicines, addressing a very under-served market in China. Itsfacility is one of the few GMP facilities licensed for narcotics medicines.The Company has two drugs on the market and has received China SFDA licensesfor seven more medications such as Oxycodone, Tilidine and Pholcodine. TheCompany is working closely with the Chinese government and SFDA to assure theavailability of narcotic drugs and pain medicines throughout China.

This news release contains forward-looking statements as defined by thePrivate Securities Litigation Reform Act of 1995. Forward-looking statementsinclude statements concerning plans, objectives, goals, strategies, futureevents or performance, and underlying assumptions and other statements thatare other than statements of historical facts. These statements are subject touncertainties and risks including, but not limited to, product and servicedemand and acceptance, changes in technology, economic conditions, the impactof competition and pricing, government regulation, and other risks containedin statements filed from time to time with the Securities and ExchangeCommission. All such forward-looking statements, whether written or oral, andwhether made by or on behalf of the company, are expressly qualified by thecautionary statements and any other cautionary statements which may accompanythe forward-looking statements. You are urged to read the Company's filingswith the Securities and Exchange Commission, including, but not limited to,the risk factors contained therein. In addition, the Company disclaims anyobligation to update any forward-looking statements to reflect events orcircumstances after the date hereof.CONTACT Dr. Hui Shao Senior Vice President China Aoxing Pharmaceutical 201-420-1075

SOURCE China Aoxing Pharmaceutical Company, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Webcast Advisory - NUCRYST Pharmaceuticals Webcast...
Synvista Announces New Data Showing Haptoglobin Ty...